Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30851263 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BAURKAKDR | |
| SCHEMBL24968228 | 0.84 | AURKA (0.37) | HTR2AHTR2CAURKAKDRAURKB | |
| SCHEMBL30851115 | 0.84 | AURKA (0.37) | HTR2AHTR2CAURKAKDRAURKB | |
| SCHEMBL21031170 | 0.82 | AURKA (0.40) | HTR2AHTR2CAURKAKDRAURKB | |
| SCHEMBL24968232 | 0.82 | ATM (0.40) | AURKAKDRAURKBATMTAAR1 | |
| SCHEMBL30851096 | 0.82 | ATM (0.40) | AURKAKDRAURKBATMTAAR1 | |
| SCHEMBL932942 | 0.81 | AURKA (0.39) | AURKAKDRAURKBPIK3R1PIK3CA | |
| SCHEMBL29208803 | 0.81 | AURKA (0.39) | AURKAKDRAURKBPIK3R1PIK3CA | |
| SCHEMBL27233788 | 0.81 | AURKA (0.39) | HTR2AHTR2CAURKAKDRAURKB | |
| SCHEMBL29165939 | 0.79 | PIK3R1 (0.36) | AURKAKDRAURKBKDM4EPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | HTR2A 3863/4885HTR2C 3458/4885HTR2B 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.